CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
巴西血液学、血液疗法与细胞治疗协会关于基因修饰细胞的共识。IV：多发性骨髓瘤患者的 CAR-T 细胞治疗
英文原题：Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients.
查看英文原题
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去十年中，随着新药的加入，尤其是蛋白酶体抑制剂、免疫调节剂和单克隆抗体，多发性骨髓瘤的治疗取得了非凡的进展。创新药物联合使用，且已进入一线治疗，使这些患者的生存率显著提高。然而，复发仍是巨大挑战，该病仍无法治愈。在这一背景下，现代免疫治疗备受瞩目，尤其是近期在临床试验中使用 CAR-T 细胞，如多发性骨髓瘤中以 BCMA 为主要靶点。对于多次复发且为三重和五重难治的多发性骨髓瘤患者，其结果具有重大影响。在本共识中，我们汇集了一组多发性骨髓瘤专家，讨论并提出他们对未来的建议，我们希望这一天很快到来，将 CAR-T 引入我国。
展开英文摘要原文
Extraordinary progress has been made over the last decade in the treatment of multiple myeloma with the incorporation of new drugs, particularly proteasome inhibitors, immunomodulators, and monoclonal antibodies. The combined use of innovative drugs, already in the first lines of treatment, has led to an expressive increase in the survival of these patients.
However, the approach to relapse remains a great challenge, and the disease continues to be incurable. In this scenario, modern immunotherapy has gained the limelight, especially with its recent use of CAR-T cells in clinical trials, as in the case of multiple myeloma, having the BCMA as the primary target.
The results are impactful in the treatment of multiple myeloma patients who have had multiple relapses and are triple- and penta-refractory. In this Consensus, we have brought together a group of experts in multiple myeloma to discuss and forward their recommendations for the future, which we hope is very near, incorporating the CAR-T in our country.
论文信息
- 作者
- Maiolino A、Costa LJ、Pasquini M、Crusoe EQ、Vigorito AC、Salvino MA、Seguro FS、Filho JS
- 单位
- Faculdade de Medicina, Universidade Federal do Rio de Janeiro (FM UFRJ), Rio de Janeiro, RJ, Brazil; Americas Oncologia Rio de Janeiro, Rio de Janeiro, RJ, Brazil. Electronic address: maiolino@hucff.ufrj.br.Brazil
- 期刊
- Hematology, transfusion and cell therapy2021 Nov
- 原文标识
- PubMed 34794794 · DOI 10.1016/j.htct.2021.09.004
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →